KetoSwiss

KetoSwiss is a privately held Swiss biotechnology company located in Basel, that develops a novel nutraceutical / medical food (“MigraKet”) for the dietary preventive therapy of higher-frequency migraines and possibly other related diseases characterized by a metabolic dysfunction (such as Alzheimer's Disease). The lead product’s active substance is an endogenous metabolite – a ketone body, which can be used by the brain as an alternative fuel to glucose, when glucose utilization or transport is compromised.  Due to our modern carbohydrate-rich diets our brains rely almost exclusively on glucose. This can contribute to an energy-deficiency in the brain and in turn neurological diseases, such as migraine or Alzheimers, which are known to have a metabolic component to it. During fasting / glucose restriction our livers  produce an alternative, more effective fuel source for the brain called ketone bodies. KetoSwiss strives to bring human identical ketone bodies back into our modern world. We develop potent, clinically tested, Swiss quality ketone body products (esp. medical foods) to combat neurological civilisation diseases.

In brief, KetoSwiss makes fuel for brains.

 

KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where the company is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem. KetoSwiss enjoys broad access to state-of-the art infrastructure as well as laboratories to grow its operations. 

Management Team

  • Dr. Elena Gross Li

Dr. Elena Gross

Founder & CEO/CSO

Dr. Elena Gross holds a BSc in Psychology (University of York), an MSc in Neuroscience (University of Oxford) a PhD (Dr. sc. med) in Clinical Research (University of Basel) and is currently enrolled to complete her MBA (University of Cambridge). She used to be a chronic migraine patient. She is the inventor of two patents.

  • Matthias Waehren Li

Matthias Währen

Chief Financial Officer

Matthias Währen is ex-CFO & member of the Executive Committee of Givaudan SA for twelve years, previously Global Head of Finance at Roche Vitamin Division, Finance Director Roche USA, Roche Japan,  Roche Korea (amongst others).

  • Dr. Adrian Soto

Dr. Sebastian Hersberger

Chief Operating Officer

Dr. Sebastian Hersberger holds a PhD in Financial Management and has more than ten years of experience working with companies on topics such as driving extensive and sustainable growth, designing and implementing business operations and effective operational & financial procedures

 

Board of Advisors

  • PS-Li

Peter Stähli

Business & Strategy Advisor

Founder of several startups and the Swiss Economic Forum (of which he was CEO until 2016). Moreover, Peter successfully advised several startups and owns a very strong national and international network.

  • JS-Li

Prof. Dr. Jan Schoenen

Scientific & Clinical Advisor

Former President of the International Headache So-ciety & Belgian Neurological Society, research Director, full Professor at Liège Uni-versity & Associate Editor of Cephalalgia. World expert on metabolism and migrai-ne, with over 908 publica-tions (H index: 56 after 1996), 92 book chapters & 4 books

  • JS-Li

Matthias Währen

Financial, Business & Strategy Adviser

Matthias Währen is ex-CFO & member of the Executive Committee of Givaudan SA for twelve years, previously Global Head of Finance at Roche Vitamin Division, Finance Director Roche USA, Roche Japan,  Roche Korea (amongst others).

  • ZC-Li

Daniel Lustenberger

Financial, Business & Strategy Advisor

Daniel Lustenberger is an experienced international finance, accounting and management consulting professional. He is a Swiss Certified Public Accountant, holds an Executive MBA from IMD and has 20 years life sciences and technology experience. Daniel is involved with several start-ups and growth companies, particularly in the life science and high technology sector as part-time CFO, business advisor or board member. 

  • ZC-Li

Dr. Zameel Cader

Strategic Advisor

Dr. Zameel Cader is cur-rently Head of the Oxford Translational Molecular Neu-roscience Group. He is a senior clinical academic researcher, with a track record in translational me-dical research.

He furthermore successfully lead large-scale academic/ industry partnerships with societal impact.

  • ZC-Li

Dr. Thomas Beck

Business & Strategy Advisor

Dr. Thomas Beck  was the former head of the Nestle research centre and is now head of R&D at DSM. He brings a wealth of experience in the supplement / nutraceutical and life s/ health sciences industry and an extensive network.

Dr. Egle B. Thomas

Business & Strategy Advisor

Dr. Egle B. Thomas has over 20 years of experience in business strategy, business development, and R&D project management in Europe and the US. She drove activities across nutrition, agricultural and related industries while at Syngenta as well as smaller companies.  She serves on boards of companies and investment groups and advises startups in Europe and the US.

Dr. Timm Trenktrog

Supply Chain/Regulatory Expert

Dr. Timm Trenktrog holds a PhD in Pharmaceutical Technology and has more than twenty years of experience in build and managing supplier network for clinical and commercial manufacturing for drug substances, drug products, and packaging.

 

Outsourced Functions

  • NM-Li

Dr. Nicolas Mosimann

Legal

  • PM-Li

Dr. Philipp Marchand

Patent Issues

  • SM-Li

Sebastian Melchor

Complex Regulatory Affairs

  • US-Li

Urs Santschi

Finance & Accounting

Latest KetoSwiss News

Selected for Venture Leaders Life Sciences 2020

Selected for Venture Leaders Life Sciences 2020

KetoSwiss AG has been selected as Top 10 Swiss National Startup Team in Life Science and is now member of Venture Leaders Life Sciences 2020.

Dr. Egle B. Thomas joins KetoSwiss AG

Dr. Egle B. Thomas joins KetoSwiss AG

Dr. Egle B. Thomas joins KetoSwiss AG as Business & Strategy Advisor. Welcome!

First patent got all claims approved

First patent got all claims approved

A huge step towards the product protection, we will keep you posted.

Final product (MigraKet4) developed

Final product (MigraKet4) developed

Looking back at 4 years of development, KetoSwiss AG has finalised its product. In a next step, clinical trials will be conducted - we keep you posted.

Dr. Timm Trenktrog joins KetoSwiss

Dr. Timm Trenktrog joins KetoSwiss

Welcome Dr. Timm Trenktrog! He joins KetoSwiss AG as Advisor for Supply Chain/Regulatory Expert

Dr. Sebastian Hersberger joins KetoSwiss AG

Dr. Sebastian Hersberger joins KetoSwiss AG

The KetoSwiss team is enriched by Sebastian, an expert in business development and financial management, who joins KetoSwiss AG as Chief Operating Officer. Welcome!

KetoSwiss extents its portfolio to Alzheimer's

KetoSwiss extents its portfolio to Alzheimer's

In addition to migraine, KetoSwiss will clinical test the efficacy of its lead product in Alzheimer's Disease with the first randomised controlled trial starting in summer 2019.

Swiss Innovation Challenge participation

Swiss Innovation Challenge participation

KetoSwiss is taking part in the Swiss Innovation Challenge and made it to the second round - we keep you posted.

Daniel Lustenberger joins KetoSwiss AG

Daniel Lustenberger joins KetoSwiss AG

KetoSwiss welcomes Daniel Lustenberger as Financial, Business & Strategy Advisor.

Swiss Innovation Challenge

Swiss Innovation Challenge

KetoSwiss achieved 5th place at the Swiss Innovation Challenge.

First pharmacokinetic trial completed

First pharmacokinetic trial completed

The first PK trial on healthy subjects has been completed, the second is starting soon.

KetoSwiss completes Seed Funding round

KetoSwiss completes Seed Funding round

KetoSwiss raised CHF 0.5 million in a first seed funding round.

 

© 2019 by KetoSwiss AG

  • LinkedIn
  • Twitter
  • Facebook
  • Instagram

KetoSwiss AG

Sperrstrasse 10

4057 Basel

Switzerland